Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 11Myeloid 7Thoracic 1Sarcoma 1Other solid neoplasm 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 58Busulfan 47fludarabine phosphate 45Cyclosporine 34Mycophenolic Acid 31Whole-Body Irradiation 29Peripheral Blood Stem Cell Transplantation 29fludarabine 27Antilymphocyte Serum 27Tacrolimus 26Methotrexate 25Melphalan 25Filgrastim 20Radiotherapy 19Darbepoetin alfa 19Cytarabine 19Cord Blood Stem Cell Transplantation 18Epoetin Alfa 17Granulocyte Colony-Stimulating Factor 14Methylprednisolone 13thymoglobulin 10Thiotepa 9Etoposide 9Alemtuzumab 9eltrombopag 8Stem Cell Transplantation 8olaparib 7sargramostim 6hetrombopag 6Rituximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × decitabine and cedazuridine drug combination × Classical hematology × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡